tetano
Editor, Senior Moderator
Commun Dis Intell (2018). 2019 Jun 17;43. doi: 10.33321/cdi.2019.43.25.
[h=1]Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2017[/h] Roe M[SUP]1[/SUP], Kaye M[SUP]1[/SUP], Iannello P[SUP]1[/SUP], Lau H[SUP]1[/SUP], Buettner I[SUP]1[/SUP], Tolosa MX[SUP]1,[/SUP][SUP]2[/SUP], Zakis T[SUP]1[/SUP], Leung VK[SUP]1[/SUP], Chow MK[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] As part of its role in the World Health Organization?s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a record total of 5866 human influenza positive samples during 2017. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties and were propagated in qualified cells and hens? eggs for use as potential seasonal influenza vaccine virus candidates. In 2017, influenza A(H3) viruses predominated over influenza A(H1)pdm09 and B viruses, accounting for a total of 54% of all viruses analysed. The majority of A(H1)pdm09, A(H3) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO recommended vaccine strains for the Southern Hemisphere in 2017. However, phylogenetic analysis indicated that the majority of circulating A(H3) viruses had undergone genetic drift relative to the WHO recommended vaccine strain for 2017. Of 3733 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, only two A(H1)pdm09 viruses and one A(H3) virus showed highly reduced inhibition by oseltamivir, while just one A(H1)pdm09 virus showed highly reduced inhibition by zanamivir.
? Commonwealth of Australia CC BY-NC-ND
[h=4]KEYWORDS:[/h] GISRS; influenza; vaccines; surveillance; laboratory; annual report; WHO
PMID: 31203585
[h=1]Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2017[/h] Roe M[SUP]1[/SUP], Kaye M[SUP]1[/SUP], Iannello P[SUP]1[/SUP], Lau H[SUP]1[/SUP], Buettner I[SUP]1[/SUP], Tolosa MX[SUP]1,[/SUP][SUP]2[/SUP], Zakis T[SUP]1[/SUP], Leung VK[SUP]1[/SUP], Chow MK[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] As part of its role in the World Health Organization?s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a record total of 5866 human influenza positive samples during 2017. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties and were propagated in qualified cells and hens? eggs for use as potential seasonal influenza vaccine virus candidates. In 2017, influenza A(H3) viruses predominated over influenza A(H1)pdm09 and B viruses, accounting for a total of 54% of all viruses analysed. The majority of A(H1)pdm09, A(H3) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO recommended vaccine strains for the Southern Hemisphere in 2017. However, phylogenetic analysis indicated that the majority of circulating A(H3) viruses had undergone genetic drift relative to the WHO recommended vaccine strain for 2017. Of 3733 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, only two A(H1)pdm09 viruses and one A(H3) virus showed highly reduced inhibition by oseltamivir, while just one A(H1)pdm09 virus showed highly reduced inhibition by zanamivir.
? Commonwealth of Australia CC BY-NC-ND
[h=4]KEYWORDS:[/h] GISRS; influenza; vaccines; surveillance; laboratory; annual report; WHO
PMID: 31203585